# US 2026/0091018 A1 · Combination preparation containing heterocyclidene acetamide derivative

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0091018 A1
- Document ID: US20260091018A1
- Status: Published application
- Kind: A1
- Application number: 19/114,902
- Filed: 2023-09-28
- Published: 2026-04-02
- Earliest claimed: 2022-09-29
- Assignees: Senju Pharmaceutical Co., Ltd.; Mochida Pharmaceutical Co., Ltd.
- Applicants: Senju Pharmaceutical Co., Ltd.; Mochida Pharmaceutical Co., Ltd.
- Inventors: Yuki YAMASHITA
- Web page: https://patentgrep.com/patent/US20260091018A1

## CPC

- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61P 27/04: Artificial tears; Irrigation solutions
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/10: Dispersions; Emulsions
- A61K 31/196: the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K 31/7084: Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
- A61K 31/728: Hyaluronic acid
- A61K 38/13: Cyclosporins
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides a suspension-type ophthalmic solution having excellent re-dispersibility. More specifically, the present disclosure provides a water-based suspension preparation containing a first component and a second component, in which the first component is (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl) acetamide or a pharmaceutically acceptable salt or solvate thereof, and the second component comprises at least one component selected from the group consisting of diquafosol, ciclosporin, hyaluronic acid, loteprednol etabonate, bromfenac, fluorometholone and pharmaceutically acceptable salts or solvates thereof.

## Claims

### Claim 1

An aqueous suspension liquid formulation comprising:
a first component; and
a second component,
the first component being (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl) acetamide or a pharmaceutically acceptable salt or solvate thereof, and
the second component being at least one selected from the group consisting of diquafosol, cyclosporine, hyaluronic acid, loteprednol etabonate, bromfenac, fluorometholone, and a pharmaceutically acceptable salt or solvate thereof.

### Claim 2 (depends on 1)

The aqueous suspension liquid formulation according to claim 1, further comprising a nonionic surfactant.

### Claim 3 (depends on 2)

The aqueous suspension liquid formulation according to claim 2, wherein the nonionic surfactant is at least one selected from the group consisting of tyloxapol, polysorbate 80, polyethylene glycol monostearate 40, and a polyoxyethylene hydrogenated castor oil 60.

### Claim 4 (depends on 2)

The aqueous suspension liquid formulation according to claim 2, wherein the nonionic surfactant is tyloxapol.

### Claim 5 (depends on 2)

The aqueous suspension liquid formulation according to claim 2, wherein the nonionic surfactant has a concentration of about 0.0001 w/v % to about 1 w/v % in the aqueous suspension liquid formulation.

### Claim 6 (depends on 1)

The aqueous suspension liquid formulation according to claim 1, wherein the first component has a concentration of about 0.01 w/v % to about 5 w/v % in the aqueous suspension liquid formulation.

### Claim 7 (depends on 1)

The aqueous suspension liquid formulation according to claim 1, wherein the diquafosol or a pharmaceutically acceptable salt or solvate thereof has a concentration of about 0.3 w/v % to about 10 w/v % in the aqueous suspension liquid formulation;
the cyclosporine or a pharmaceutically acceptable salt or solvate thereof has a concentration of about 0.005 w/v % to about 0.5 w/v % in the aqueous suspension liquid formulation;
the hyaluronic acid or a pharmaceutically acceptable salt or solvate thereof has a concentration of about 0.01 w/v % to about 1 w/v % in the aqueous suspension liquid formulation;
the loteprednol etabonate or a pharmaceutically acceptable salt or solvate thereof has a concentration of about 0.025 w/v % to about 2.5 w/v % in the aqueous suspension liquid formulation;
the bromfenac or a pharmaceutically acceptable salt or solvate thereof has a concentration of about 0.01 w/v % to about 1 w/v % in the aqueous suspension liquid formulation; and
the fluorometholone or a pharmaceutically acceptable salt or solvate thereof has a concentration of about 0.01 w/v % to about 1 w/v % in the aqueous suspension liquid formulation.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The aqueous suspension liquid formulation according to any one of claims 1 to 7, wherein the first component is (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl) acetamide or a pharmaceutically acceptable salt or solvate thereof.
